Kymera · conference-presentation
Kymera | Results Presentation Deck | 63 slides
63 pages · 4 arc beats · 2 loops
Kymera | Results Presentation Deck | 63 slides
Kymera · 2022-12 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
15101520253035404550556063
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 63 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem Identification 4 slides 100% 4/4 slides 100% 4/4 slides · 12 hits — 0/4 slides
— 0/4 slides
— 0/4 slides
100% 4/4 slides — 0/4 slides
Agitation 11 slides 100% 11/11 slides 100% 11/11 slides · 46 hits — 0/11 slides
— 0/11 slides
27.3% 3/11 slides 100% 11/11 slides 18.2% 2/11 slides Solution 25 slides 100% 25/25 slides 100% 25/25 slides · 108 hits — 0/25 slides
20% 5/25 slides 16% 4/25 slides 100% 25/25 slides 8% 2/25 slides Action 23 slides 100% 23/23 slides 100% 23/23 slides · 95 hits — 0/23 slides
56.5% 13/23 slides 21.7% 5/23 slides 100% 23/23 slides — 0/23 slides
Slide inventory
63 every slide · same image gating as the playbook
05
The slide uses color coding to distinguish between Oncology (dark blue) and Immunology-Inflammation (orange) programs.plan_implementation
Open slide detailBeat · Agitation
08
Includes a table of prevalence/incidence for specific indications and a biological pathway diagram.size_opportunity
Open slide detailBeat · Agitation
09
The slide uses a dual-panel layout: left shows tumor volume reduction over time with weekly dosing; right shows PK/PD relationship highlighting the 48-hour windanalyze_data
Open slide detailBeat · Agitation
10
The slide uses a process flow diagram to illustrate the transition from dose escalation to expansion cohorts.plan_implementation
Open slide detailBeat · Agitation
12
PK parameters include Cmax, AUC, Vd, CL, and t1/2 with associated coefficients of variation.analyze_data
Open slide detailBeat · Agitation
13
The slide validates clinical findings against preclinical models.analyze_data
14
DL = Dose Level; DLT = Dose Limiting Toxicity; SAE = Serious Adverse Event.summarize
16
Includes a biological pathway diagram showing signaling cascades and a table of prevalence/incidence for three specific lymphoma types.diagnose_problem
Open slide detailBeat · Solution
17
Shows efficacy data (tumor volume) alongside PK/PD mechanism data (degradation over time).analyze_data
Open slide detailBeat · Solution
18
The slide uses a process flow diagram to illustrate dose escalation steps (0.16 to DLX) and a table for study objectives.plan_implementation
Open slide detailBeat · Solution
19
The slide highlights the absence of dose-limiting toxicities (DLTs) and serious adverse events (SAEs) in the initial dose cohorts.summarize
Open slide detailBeat · Solution
20
The chart shows a log-scale y-axis for plasma concentration. The table summarizes Cmax, AUCinf, Vd, CL, and t1/2 for both dose levels.analyze_data
Open slide detailBeat · Solution
21
The slide uses line charts for longitudinal PBMC data and a bar chart for tumor knockdown data, supported by summary tables.analyze_data
Open slide detailBeat · Solution
22
POM = Proof of Mechanism; PK = Pharmacokinetics; PD = Pharmacodynamics; DL = Dose Level; KD = Knockdown; DLT = Dose-Limiting Toxicity; SAE = Serious Adverse Evesummarize
Open slide detailBeat · Solution
24
The slide uses a biological pathway diagram to contrast the 'scaffolding' and 'kinase' roles of IRAK4, arguing that degradation blocks both, whereas inhibitors present_solution
Open slide detailBeat · Solution
25
Includes mechanism illustration, dose-response curves, and a comparative table of IC50 values.analyze_data
Open slide detailBeat · Solution
26
Includes a mechanism of action diagram, a market data table, and a callout box for competitive limitations.size_opportunity
Open slide detailBeat · Solution
27
The slide outlines a multi-part clinical trial (Parts A, B, and C) with specific dosing, randomization, and outcome metrics.present_framework
Open slide detailBeat · Solution
30
The table uses specific clinical metrics (HS-PGA, vIGA-AD, AN count, EASI score) to characterize the study populations.analyze_data
Open slide detailBeat · Solution
31
The table includes sub-categorization of completed treatments by severity levels.analyze_data
Open slide detailBeat · Solution
33
Includes three distinct charts: a line chart for PK over time, a scatter plot for PK/PD correlation, and a box plot for IRAK4 levels.analyze_data
Open slide detailBeat · Solution
34
Data represents Part C: 75 mg QD (fed). Error bars represent standard error (SE).analyze_data
Open slide detailBeat · Solution
35
The chart uses a dotted horizontal line to indicate the baseline level of healthy subjects for visual comparison.analyze_data
37
The slide highlights that all reported adverse events were mild (except one severe headache) and all patients recovered.analyze_data
Open slide detailBeat · Solution
38
Data presented as mean change from baseline with 90% CI. n=9 for MAD3 and n=20 for Part C (n=19 for day 14).analyze_data
Open slide detailBeat · Solution
40
The slide uses a grouped bar chart format to compare efficacy across three cohorts for two different stimulation conditions (LPS and R848).analyze_data
Open slide detailBeat · Solution
42
The slide uses individual patient IDs on the y-axis and log2 fold change on the x-axis to visualize gene expression changes.analyze_data
Open slide detailBeat · Action
46
Includes error bars representing standard error of the mean.analyze_data
Open slide detailBeat · Action
47
Data presented as line charts with error bars representing standard error or confidence intervals.analyze_data
Open slide detailBeat · Action
48
The chart tracks 7 patients over time, showing a shift from severe/moderate to mild categories.analyze_data
Open slide detailBeat · Action
49
Includes clinical photography, efficacy endpoint table, and biomarker data (cytokines and RNAseq).illustrate_case
Open slide detailBeat · Action
50
The slide uses a comparison table to highlight the efficacy of KT-474 against external benchmarks.compare_peers
Open slide detailBeat · Action
52
Data compares 'All HS' vs 'Moderate to Severe' patient cohorts. Includes error bars representing standard error or 80% confidence intervals.analyze_data
Open slide detailBeat · Action
53
The chart displays response rates for 'All HS' and 'Moderate to Severe' cohorts with 80% confidence intervals.analyze_data
Open slide detailBeat · Action
54
Data presented as line charts with error bars for two patient cohorts.analyze_data
Open slide detailBeat · Action
55
The chart displays longitudinal clinical trial data with error bars representing standard error of the mean.analyze_data
Open slide detailBeat · Action
56
The charts track patient status from baseline to day 42. The left chart includes 12 patients, the right chart includes 10 patients.analyze_data
Open slide detailBeat · Action
57
The slide uses a before-after framework to demonstrate clinical efficacy.illustrate_case
Open slide detailBeat · Action
58
Includes patient demographics, clinical efficacy table, before/after photos, and a line chart of cytokine/reactant levels.illustrate_case
Open slide detailBeat · Action
59
The slide uses a comparison table to highlight efficacy metrics across different clinical endpoints.compare_peers
Open slide detailBeat · Action